Literature DB >> 8144342

Physicochemical parameters of x-ray contrast media.

W Krause1, H Miklautz, U Kollenkirchen, G Heimann.   

Abstract

RATIONALE AND
OBJECTIVES: Osmolality, including "dynamic osmolality," which is observed during dilution in the plasma, viscosity, density, and partition coefficient of 11 commercially available contrast media and two new nonionic monomers were determined.
METHODS: Osmolality was measured by vapor pressure osmometry, viscosity by determining flow in microcapillaries, and partition coefficient in n-octanol or n-butanol/water mixtures by inductively coupled plasma mass spectroscopy or x-ray fluorescence analysis of iodine concentrations.
RESULTS: For the commercially available contrast media, the following statistically significant ranking of osmolality was obtained at 300 mg iodine/mL: iotrolan << ioxaglate < iopromide < iopamidol < ioversol = iohexol < iopentol << meglumine diatrizoate. The novel nonionic monomers, ZK 119095 and ZK 139129, had very low osmolalities, and ZK 139129 was isotonic to blood. The partition coefficient for the system n-octanol/water was lowest for the ionic compounds ioxaglate and diatrizoate followed by the nonionic dimer iotrolan. In n-butanol, iotrolan showed the lowest partition coefficient.
CONCLUSION: "Dynamic osmolalities" of contrast media may differ from static values possibly because of the formation of "quasi-oligomers." Especially for ZK 139129, disaggregation occurred during dilution and the osmolality increased slightly. However, osmolality was lower than for any other monomer during the whole dilution process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144342     DOI: 10.1097/00004424-199401000-00015

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  2 in total

1.  X-ray contrast media mechanisms in the release of mast cell contents: understanding these leads to a treatment for allergies.

Authors:  Elliott C Lasser
Journal:  J Allergy (Cairo)       Date:  2011-09-15

2.  Risk of Hypersensitivity Reactions to Iopromide After Intra-Arterial Versus Intravenous Administration: A Nested Case-Control Analysis of 133,331 Patients.

Authors:  Jan Endrikat; Alexander Michel; Ralf Kölbach; Philipp Lengsfeld; Kai Vogtländer
Journal:  Invest Radiol       Date:  2020-01       Impact factor: 10.065

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.